These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)? Dupuis-Girod S; Shovlin CL; Kjeldsen AD; Mager HJ; Sabba C; Droege F; Fargeton AE; Fialla AD; Gandolfi S; Hermann R; Lenato GM; Manfredi G; Post MC; Rennie C; Suppressa P; Sure U; ; Buscarini E Eur J Med Genet; 2022 Oct; 65(10):104575. PubMed ID: 35940549 [TBL] [Abstract][Full Text] [Related]
3. Clinical features and treatment of hereditary hemorrhagic telangiectasia. Li S; Wang SJ; Zhao YQ Medicine (Baltimore); 2018 Aug; 97(31):e11687. PubMed ID: 30075565 [TBL] [Abstract][Full Text] [Related]
4. Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study. Fang J; Chen X; Zhu B; Ye H; Zhang W; Guan J; Su K Otolaryngol Head Neck Surg; 2017 Aug; 157(2):217-221. PubMed ID: 28418273 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517 [TBL] [Abstract][Full Text] [Related]
6. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia]. Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875 [TBL] [Abstract][Full Text] [Related]
7. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers. Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN Orphanet J Rare Dis; 2019 Nov; 14(1):256. PubMed ID: 31727111 [TBL] [Abstract][Full Text] [Related]
8. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646 [TBL] [Abstract][Full Text] [Related]
9. Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. Penaloza A; Vekemans MC; Lambert C; Hermans C Blood Coagul Fibrinolysis; 2011 Oct; 22(7):616-8. PubMed ID: 21885956 [TBL] [Abstract][Full Text] [Related]
10. Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model. Peng HL; Yi YF; Zhou SK; Xie SS; Zhang GS Chin Med J (Engl); 2015 Nov; 128(22):3050-4. PubMed ID: 26608985 [TBL] [Abstract][Full Text] [Related]
11. Genetic Diagnosis of Hereditary Hemorrhagic Telangiectasia: Four Novel Pathogenic Variations in Turkish Patients. Baysal M; Demir S; Ümit EG; Gürkan H; Baş V; Karaman Gülsaran S; Demirci U; Kırkızlar HO; Demir AM Balkan Med J; 2019 Dec; 37(1):43-46. PubMed ID: 31594285 [TBL] [Abstract][Full Text] [Related]
12. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841 [TBL] [Abstract][Full Text] [Related]
13. Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life. Baysal M; Ümit EG; Kırkızlar HO; Özdöver AC; Demir AM Turk J Haematol; 2019 Feb; 36(1):43-47. PubMed ID: 29880465 [TBL] [Abstract][Full Text] [Related]
14. [Iron deficiency anemia in a patient with hereditary hemorrhagic telangiectasia. Case report]. Mozdon MA; Ponomarev RV; Tsvetaeva NV; Shabrin AV; Ermachenkova EI; Larichev SE; Lukina EA Ter Arkh; 2023 Sep; 95(7):580-585. PubMed ID: 38159009 [TBL] [Abstract][Full Text] [Related]
15. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Lebrin F; Srun S; Raymond K; Martin S; van den Brink S; Freitas C; Bréant C; Mathivet T; Larrivée B; Thomas JL; Arthur HM; Westermann CJ; Disch F; Mager JJ; Snijder RJ; Eichmann A; Mummery CL Nat Med; 2010 Apr; 16(4):420-8. PubMed ID: 20364125 [TBL] [Abstract][Full Text] [Related]
16. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Al-Samkari H; Kasthuri RS; Parambil JG; Albitar HA; Almodallal YA; Vázquez C; Serra MM; Dupuis-Girod S; Wilsen CB; McWilliams JP; Fountain EH; Gossage JR; Weiss CR; Latif MA; Issachar A; Mei-Zahav M; Meek ME; Conrad M; Rodriguez-Lopez J; Kuter DJ; Iyer VN Haematologica; 2021 Aug; 106(8):2161-2169. PubMed ID: 32675221 [TBL] [Abstract][Full Text] [Related]
17. Mutational and clinical spectrum of Japanese patients with hereditary hemorrhagic telangiectasia. Kitayama K; Ishiguro T; Komiyama M; Morisaki T; Morisaki H; Minase G; Hamanaka K; Miyatake S; Matsumoto N; Kato M; Takahashi T; Yorifuji T BMC Med Genomics; 2021 Dec; 14(1):288. PubMed ID: 34872578 [TBL] [Abstract][Full Text] [Related]
18. [Effects of bevacizumab on familial epistaxis caused by hereditary hemorrhagic telangiectasia]. Zhang J; Wang XS; Wang HT Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 May; 56(5):436-441. PubMed ID: 34010995 [No Abstract] [Full Text] [Related]